



Docket No.: 31075/40037
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Zankel *et al*

Application No.: 10/812,849

Group Art Unit: 1649

Filing Date: March 30, 2004

Examiner: D. Kolker

For: Megalin Based Delivery of Therapeutic Compounds to the Brain and Other Tissues

DECLARATION UNDER 37 C.F.R. § 1.132 OF DR. TODD ZANKEL

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

I, Dr. Todd Zankel, do hereby declare and state as follows:

DK
considered
6/26/07

1. I am a co-inventor of the invention claimed in the above-referenced application.
2. The following experiments were carried out at my direction and under my supervision. The construction of a RAP fragment as described was readily accomplished with only routine effort.
3. A C-terminal fragment of RAP starting at amino acid 201 of mature RAP and lacking the HNEL endoplasmic reticulum retention signal at the C-terminus, was prepared. Briefly, cDNA encoding this fragment was ligated into Novagen vector pET30+, the vector was expressed in *E. coli* BL21(DE3) cells, and the RAP fragment was purified generally as described in WO 2006/138343, an application on which I am a named inventor. This RAP d3 fragment consisted of amino acids 201-319 of SEQ ID NO: 1.